Drugs / Porfiromycin
Porfiromycin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02209701 | Dec 1999 → Jul 2000 | head and neck neoplasm | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02183246 | May → Dec 2000 | head and neck neoplasm | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT00003328 | Dec 1997 → ? | head and neck cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00002507 | Nov 1992 → Oct 2002 | cancer of unknown primary site, head and neck cancer | Yale University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | porfiromycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002507 ↗ |
| Known as | N-methylmitomycin c | ChEMBL registry synonym — accepted as the source's own label CHEMBL521078 ↗ |
| Known as | NSC-56410 | “plus Porfiromycin, NSC-56410” NCT00002507 ↗ |
| Known as | Porfiromicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL521078 ↗ |
| Known as | Porfiromycine | ChEMBL registry synonym — accepted as the source's own label CHEMBL521078 ↗ |
| Known as | U-14,743 | ChEMBL registry synonym — accepted as the source's own label CHEMBL521078 ↗ |
| Modality | Small molecule | — CHEMBL521078 ↗ |
| Route | Intravenous | “Patients receive porfiromycin or placebo by intravenous infusion over 30-60 minutes on day 5 and then on day 46 or 47.” NCT00003328 ↗ |